London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Twelve month results after stand-alone implantation of CyPass Micro-Stent in patients with open-angle glaucoma in Bulgaria

Poster Details

First Author: T.Ianchulev USA

Co Author(s):    P. Guguchkova   B. Samsonova   A. Topov        

Abstract Details



Purpose:

To evaluate the CyPass Micro-Stent (Transcend Medical, Inc., Menlo Park, CA, USA), a supraciliary, ab interno implant, as a standalone treatment for patients with open-angle glaucoma (OAG) unresponsive to topical therapies in a single center in Bulgaria.

Setting:

Single-center, interventional, prospective, consecutive case series

Methods:

The implant was placed ab interno through a corneal incision under gonioscopic visualization as a standalone procedure. Medications were stopped following the procedure and re-introduced per the investigator's decision and the subject's intraocular pressure (IOP) target. Main outcomes were adverse events, IOP changes, and number of IOP-lowering medications at baseline and 1 year.

Results:

Eyes (n=17) were enrolled. There were no major adverse events. High IOP occurred in 3 subjects (17.6%). Transient hypotony occurred in 1 subject (5.9%) but was resolved in the first month. At baseline, subjects had mean ± SD baseline IOP (n=17) was 24.2 ± 5.2 mmHg and mean ± SD medication usage was 2.1 ± 1.1 medications. At 12 months, subjects had a mean ± SD IOP of 17.6 ± 5.4 mmHg (n=15), representing a 23% reduction, with mean ± SD medication usage of 1.3 ± 0.9 medications.

Conclusions:

The CyPass Micro-Stent is a safe and effective standalone treatment for open-angle glaucoma patients unresponsive to medications. FINANCIAL INTEREST: One of more of the authors... is employed by a forNONEprofit company with an interest in the subject of the presentation, One of more of the authors... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One of more of the authors... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to Poster listing